Novo Nordisk, other companies meet Danish prime minister following Trump's Greenland threat By Reuters
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2025
0mins
Should l Buy NVO?
Source: Investing.com
Danish Prime Minister's Meeting: Denmark's Prime Minister Mette Frederiksen met with business leaders, including the CEO of Novo Nordisk, to discuss potential trade conflicts with the U.S. regarding Greenland after President-elect Trump hinted at military or economic actions to acquire the territory.
Impact on Danish Companies: Frederiksen emphasized the importance of Danish companies in contributing to U.S. growth and jobs, while expressing concerns over possible reduced cooperation between Denmark and the U.S. if trade tensions escalate.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 49.370
Low
42.00
Averages
54.67
High
70.00
Current: 49.370
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Expects Earnings Decline in 2026
- Earnings Guidance Decline: Novo Nordisk's 2025 earnings report revealed a grim outlook for 2026, with sales and earnings expected to decline between 5% and 13%, primarily due to lower GLP-1 drug prices in the U.S., indicating significant market pressures and uncertainty regarding future profitability.
- Surge in GLP-1 Demand: Despite these challenges, the company's new GLP-1 pill attracted 170,000 patients within just four weeks of launch, far exceeding management's expectations, highlighting the potential growth opportunities in the weight-loss drug market.
- Increased Market Acceptance: The preference for oral medications over injections among consumers suggests that Novo Nordisk's GLP-1 pill could tap into a larger market, and the pricing agreement with the U.S. government further boosts demand, creating a favorable environment for sales growth.
- Optimistic Long-Term Outlook: Although Novo Nordisk's stock has lost two-thirds of its value since its peak in 2024, the early success of the pill indicates that future volume could offset the pricing pressures expected in 2026, with the CEO's comments reflecting a positive internal outlook for the company's future.
See More
Novo Nordisk Shares Surge After Competitor Withdraws Drug
- Stock Surge: Novo Nordisk shares jumped 8% on Monday following Hims & Hers' announcement to withdraw its copycat weight-loss pill, indicating increased market confidence in Novo Nordisk's products.
- Legal Threats: Novo Nordisk and the FDA had threatened legal action against Hims & Hers, prompting the withdrawal, which not only protects Novo Nordisk's market share but may also reshape competitive dynamics in the industry.
- Market Reaction: Hims & Hers stated on social media that after constructive conversations with industry stakeholders, they decided to stop offering the treatment, a move that could further solidify Novo Nordisk's leadership in the weight-loss drug market.
- Commitment to Safe Care: Hims & Hers emphasized its commitment to providing safe, affordable, and personalized care, and while the withdrawal may impact its trust among consumers, it reflects a strategic pivot in response to regulatory pressures.
See More
MrBeast Acquires Financial App Step Amid Market Gains
- MrBeast Enters Finance: YouTuber Jimmy Donaldson, known as MrBeast, announced the acquisition of financial services app Step, marking his expansion into fintech, which could attract younger users and enhance brand influence.
- Coca-Cola's Mixed Results: Coca-Cola reported adjusted earnings per share that exceeded expectations for Q4, but its adjusted revenue of $11.82 billion fell short of the $12.03 billion forecast, indicating weakening consumer demand that may impact future growth.
- Alphabet's AI Investment Surge: Alphabet plans to raise $20 billion through a U.S. dollar bond sale to fund its AI initiatives, with capital expenditures in 2026 expected to exceed those of 2025, highlighting the company's commitment to AI despite associated risks.
- Target Restructures Workforce: Target announced in an internal memo that it will increase store staffing while cutting around 500 jobs at distribution centers and regional offices to enhance customer shopping experiences, reflecting the new CEO's focus on improving customer satisfaction.
See More
MrBeast Acquires Financial Services App Step
- MrBeast Enters Finance: YouTuber Jimmy Donaldson, known as MrBeast, announced the acquisition of the financial services app Step, marking his expansion into fintech, which could attract younger users and enhance his brand influence.
- Coca-Cola's Mixed Earnings: Coca-Cola reported fourth-quarter adjusted earnings per share that exceeded expectations, but its adjusted revenue of $11.82 billion fell short of the $12.03 billion forecast, indicating weakening consumer demand that may impact future growth.
- Alphabet's AI Investment: Alphabet plans to raise $20 billion through a U.S. dollar bond sale to fund its AI infrastructure, while acknowledging for the first time that increased consumer use of generative AI could disrupt its core advertising business, highlighting a landscape of both risks and opportunities.
- Target Resource Shift: Target stated in an internal memo that it will increase store staffing while cutting around 500 jobs at distribution centers and regional offices to enhance customer shopping experiences, reflecting the new CEO's commitment to improving customer satisfaction.
See More
Hoth Therapeutics Reveals GDNF Study Data for Obesity Treatment
- Significant Study Results: Hoth Therapeutics' research indicates that GDNF shows remarkable efficacy in obesity and metabolic-associated steatotic liver disease, particularly in female models where weight loss reached 10-15%, contrasting with semaglutide's lack of significant impact, suggesting GDNF could be a game-changing treatment in the obesity market.
- Mechanistic Advantages: GDNF outperformed semaglutide in key metrics, including weight stabilization, improved glucose tolerance, and reduced liver weight, highlighting its potential to address limitations of current GLP-1 agonists, particularly gastrointestinal side effects and muscle loss.
- Future Research Directions: Hoth plans to accelerate GDNF toward IND-enabling studies, targeting clinical trials in 2027, with future analyses including liver pathology, lipid content, and gene/protein expression to further elucidate mechanisms.
- Broad Market Potential: With over 1 billion people affected by obesity globally and MASLD impacting up to 30% of adults, GDNF's multifaceted benefits could revolutionize treatment paradigms, making Hoth's GDNF program strategically significant within its pipeline.
See More
Eli Lilly's Dominance in the GLP-1 Market
- Market Leadership: Eli Lilly commands over 60% of the GLP-1 drug market, with Mounjaro and Zepbound driving consistent revenue growth, as evidenced by over $11 billion in combined revenue last quarter, showcasing its competitive edge in the rapidly expanding obesity drug sector.
- Revenue Growth Potential: Analysts project the obesity drug market to approach $100 billion by the end of the decade, and with Lilly's robust position and product pipeline, the company is well-positioned for sustained revenue growth over the coming decades, potentially delivering substantial returns for shareholders.
- Product Efficacy Advantage: Zepbound's superior performance in head-to-head trials against Wegovy further solidifies Lilly's market leadership, while the anticipated approval of orforglipron, which offers easier administration, is expected to generate additional growth and enhance the company's competitive stance.
- Diversified Investment Opportunity: While Eli Lilly alone may not make investors millionaires, its stock remains a valuable component of a diversified portfolio, particularly as the obesity drug market continues to expand, providing potential for significant wealth accumulation for investors.
See More
Novo Nordisk Expects Earnings Decline in 2026
- Earnings Guidance Decline: Novo Nordisk's 2025 earnings report revealed a grim outlook for 2026, with sales and earnings expected to decline between 5% and 13%, primarily due to lower GLP-1 drug prices in the U.S., indicating significant market pressures and uncertainty regarding future profitability.
- Surge in GLP-1 Demand: Despite these challenges, the company's new GLP-1 pill attracted 170,000 patients within just four weeks of launch, far exceeding management's expectations, highlighting the potential growth opportunities in the weight-loss drug market.
- Increased Market Acceptance: The preference for oral medications over injections among consumers suggests that Novo Nordisk's GLP-1 pill could tap into a larger market, and the pricing agreement with the U.S. government further boosts demand, creating a favorable environment for sales growth.
- Optimistic Long-Term Outlook: Although Novo Nordisk's stock has lost two-thirds of its value since its peak in 2024, the early success of the pill indicates that future volume could offset the pricing pressures expected in 2026, with the CEO's comments reflecting a positive internal outlook for the company's future.
See More
Novo Nordisk Shares Surge After Competitor Withdraws Drug
- Stock Surge: Novo Nordisk shares jumped 8% on Monday following Hims & Hers' announcement to withdraw its copycat weight-loss pill, indicating increased market confidence in Novo Nordisk's products.
- Legal Threats: Novo Nordisk and the FDA had threatened legal action against Hims & Hers, prompting the withdrawal, which not only protects Novo Nordisk's market share but may also reshape competitive dynamics in the industry.
- Market Reaction: Hims & Hers stated on social media that after constructive conversations with industry stakeholders, they decided to stop offering the treatment, a move that could further solidify Novo Nordisk's leadership in the weight-loss drug market.
- Commitment to Safe Care: Hims & Hers emphasized its commitment to providing safe, affordable, and personalized care, and while the withdrawal may impact its trust among consumers, it reflects a strategic pivot in response to regulatory pressures.
See More
MrBeast Acquires Financial App Step Amid Market Gains
- MrBeast Enters Finance: YouTuber Jimmy Donaldson, known as MrBeast, announced the acquisition of financial services app Step, marking his expansion into fintech, which could attract younger users and enhance brand influence.
- Coca-Cola's Mixed Results: Coca-Cola reported adjusted earnings per share that exceeded expectations for Q4, but its adjusted revenue of $11.82 billion fell short of the $12.03 billion forecast, indicating weakening consumer demand that may impact future growth.
- Alphabet's AI Investment Surge: Alphabet plans to raise $20 billion through a U.S. dollar bond sale to fund its AI initiatives, with capital expenditures in 2026 expected to exceed those of 2025, highlighting the company's commitment to AI despite associated risks.
- Target Restructures Workforce: Target announced in an internal memo that it will increase store staffing while cutting around 500 jobs at distribution centers and regional offices to enhance customer shopping experiences, reflecting the new CEO's focus on improving customer satisfaction.
See More
MrBeast Acquires Financial Services App Step
- MrBeast Enters Finance: YouTuber Jimmy Donaldson, known as MrBeast, announced the acquisition of the financial services app Step, marking his expansion into fintech, which could attract younger users and enhance his brand influence.
- Coca-Cola's Mixed Earnings: Coca-Cola reported fourth-quarter adjusted earnings per share that exceeded expectations, but its adjusted revenue of $11.82 billion fell short of the $12.03 billion forecast, indicating weakening consumer demand that may impact future growth.
- Alphabet's AI Investment: Alphabet plans to raise $20 billion through a U.S. dollar bond sale to fund its AI infrastructure, while acknowledging for the first time that increased consumer use of generative AI could disrupt its core advertising business, highlighting a landscape of both risks and opportunities.
- Target Resource Shift: Target stated in an internal memo that it will increase store staffing while cutting around 500 jobs at distribution centers and regional offices to enhance customer shopping experiences, reflecting the new CEO's commitment to improving customer satisfaction.
See More
Hoth Therapeutics Reveals GDNF Study Data for Obesity Treatment
- Significant Study Results: Hoth Therapeutics' research indicates that GDNF shows remarkable efficacy in obesity and metabolic-associated steatotic liver disease, particularly in female models where weight loss reached 10-15%, contrasting with semaglutide's lack of significant impact, suggesting GDNF could be a game-changing treatment in the obesity market.
- Mechanistic Advantages: GDNF outperformed semaglutide in key metrics, including weight stabilization, improved glucose tolerance, and reduced liver weight, highlighting its potential to address limitations of current GLP-1 agonists, particularly gastrointestinal side effects and muscle loss.
- Future Research Directions: Hoth plans to accelerate GDNF toward IND-enabling studies, targeting clinical trials in 2027, with future analyses including liver pathology, lipid content, and gene/protein expression to further elucidate mechanisms.
- Broad Market Potential: With over 1 billion people affected by obesity globally and MASLD impacting up to 30% of adults, GDNF's multifaceted benefits could revolutionize treatment paradigms, making Hoth's GDNF program strategically significant within its pipeline.
See More
Eli Lilly's Dominance in the GLP-1 Market
- Market Leadership: Eli Lilly commands over 60% of the GLP-1 drug market, with Mounjaro and Zepbound driving consistent revenue growth, as evidenced by over $11 billion in combined revenue last quarter, showcasing its competitive edge in the rapidly expanding obesity drug sector.
- Revenue Growth Potential: Analysts project the obesity drug market to approach $100 billion by the end of the decade, and with Lilly's robust position and product pipeline, the company is well-positioned for sustained revenue growth over the coming decades, potentially delivering substantial returns for shareholders.
- Product Efficacy Advantage: Zepbound's superior performance in head-to-head trials against Wegovy further solidifies Lilly's market leadership, while the anticipated approval of orforglipron, which offers easier administration, is expected to generate additional growth and enhance the company's competitive stance.
- Diversified Investment Opportunity: While Eli Lilly alone may not make investors millionaires, its stock remains a valuable component of a diversified portfolio, particularly as the obesity drug market continues to expand, providing potential for significant wealth accumulation for investors.
See More
